Novartis AG
🇨🇭Switzerland
- Country
- 🇨🇭Switzerland
- Ownership
- Public, Private
- Established
- 1996-01-01
- Employees
- 76K
- Market Cap
- $242.6B
- Introduction
Novartis develops and manufactures innovative drugs. The firm's key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
Effects of Water and Food Intake on the Pharmacokinetics and Pharmacodynamics of Oral Salmon Calcitonin in Healthy Postmenopausal Women
Phase 1
Completed
- Conditions
- Postmenopausal Osteoporosis
- First Posted Date
- 2006-11-02
- Last Posted Date
- 2007-05-28
- Lead Sponsor
- Novartis
- Target Recruit Count
- 56
- Registration Number
- NCT00395395
Effect of Valsartan on Lipid Subfractions in Hypertensive Patients With Metabolic Syndrome
Phase 3
Completed
- Conditions
- HypertensionMetabolic Syndrome
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2017-02-24
- Lead Sponsor
- Novartis
- Target Recruit Count
- 45
- Registration Number
- NCT00394745
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
VALIDATE Valsartan and Supportive Measures - Impact on Drug Adherence of Treated Hypertensive Patients
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-11-01
- Last Posted Date
- 2017-05-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 206
- Registration Number
- NCT00394823
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Efficacy, Safety and Tolerability of DNK333 (25 mg Bid) in Women With Diarrhea-predominant Irritable Bowel Syndrome (IBS-D)
Phase 2
Completed
- Conditions
- Irritable Bowel Syndrome With Diarrhea (IBS-D)
- Interventions
- Drug: Placebo
- First Posted Date
- 2006-10-31
- Last Posted Date
- 2017-02-27
- Lead Sponsor
- Novartis
- Target Recruit Count
- 180
- Registration Number
- NCT00394173
- Locations
- 🇨🇦
Investigative Site, Quebec, Canada
Efficacy, Safety, and Tolerability of Once Daily Indacaterol in Chronic Obstructive Pulmonary Disease (COPD) Using Formoterol Twice Daily as Active Control
Phase 3
Completed
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- First Posted Date
- 2006-10-27
- Last Posted Date
- 2011-08-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 1732
- Registration Number
- NCT00393458
- Locations
- 🇬🇧
Novartis Investigator Site, Swansea, United Kingdom
🇪🇸Novartis Investigative Site, Madrid, Spain
🇹🇷Novartis, Istanbul, Turkey
Efficacy and Safety of 28 or 56 Day Treatment for Pseudomonas Aeruginosa in Children With Cystic Fibrosis
Phase 3
Completed
- Conditions
- Cystic Fibrosis
- Interventions
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2011-08-29
- Lead Sponsor
- Novartis
- Target Recruit Count
- 123
- Registration Number
- NCT00391976
Maintaining Bone Strength in Men With Prostate Cancer
Phase 3
Terminated
- Conditions
- Prostate Cancer
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2009-11-23
- Lead Sponsor
- Novartis
- Target Recruit Count
- 300
- Registration Number
- NCT00391950
A Study to Evaluate the Combination of Valsartan + Amlodipine in Hypertensive Patients
Phase 3
Completed
- Conditions
- Hypertension
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 224
- Registration Number
- NCT00392262
- Locations
- 🇨🇭
Novartis, Basel, Switzerland
Efficacy of Levodopa/Carbidopa/Entacapone vs Levodopa/Carbidopa in Parkinson's Disease Patients With Early Wearing-off
Phase 4
Completed
- Conditions
- Parkinson's Disease
- Interventions
- First Posted Date
- 2006-10-25
- Last Posted Date
- 2011-03-15
- Lead Sponsor
- Novartis
- Target Recruit Count
- 95
- Registration Number
- NCT00391898
- Locations
- 🇪🇸
Fundación Hospital de Alcorcón, Alcorcón (Madrid, Spain
🇪🇸Centro Médico Teknon, Barcelona, Spain
🇪🇸Hospital de la Santa Creu i de Sant Pau, Barcelona, Spain
Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
Phase 4
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2006-10-24
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Novartis
- Target Recruit Count
- 99
- Registration Number
- NCT00391690
- Locations
- 🇩🇪
Novartis Investigative Site, Tuebingen, Germany
© Copyright 2025. All Rights Reserved by MedPath